* First Author, # Corresponding Author

2026

1. Yu SY*, Park J, Lee SJ, Kim J, Oh JK, Shin G. Male-Driven Heterogeneity in Sexual Networks and Implications for STI Control in South Korea: A National Cross-Sectional Study. Epidemiology and Health (Q2). Under review.

2. Lee SH*, Yu SY#, Kim KH#. Comparative Impact of Comorbidities on Mortality in Elderly Patients with COVID-19 and Influenza in the Post-Pandemic Era: A Nationwide Cohort Study. Epidemiology and Health (Q2). Under review.

3. Roh M*, Lee H*, Han WK, Hwang EC, Jung JH, Lee SH, Lee KS, An JE, Im H#, Yu SY#. Development and Transportability of a Risk Prediction Model for Clinically Significant Prostate Cancer: A Korean Multicenter Study. BJU International (Q1). Under review.

4. Kim JY*, Yu SY*, Bae EY, Yoon JH, Seok H, Choe YJ, Choi SJ, Oh HS, Suh JW, Cho J, Yoon YK#. National priority assessment of antimicrobial-resistant pathogens in the Republic of Korea: multicriteria decision analysis. Lancet Regional Health Western Pacific (5%). In revision. 

5. An JE*, Cheong C, Jo JW, Yu SY#. Trends in Incidence and Medical Costs of Human Papillomavirus–Related Diseases in Korea: Evidence from National Health Insurance Claims. Sexually Transmitted Infections (Q2). In press.

6. Lee AY*, Lee SH, Kim MJ, An JE, Hong GU, Sim WJ, Lim H, Kong TW, Kwon BS, Park ST, So KA, Lee WM, Lee JY, Jeong DH, Choi MC, Choi YJ, Lee JK, Min KJ, Yu SY#. Validity of HINT-8 in evaluating health-related quality of life among cervical cancer patients. Journal of Comparative Effectiveness Research (Q2). In press. 

7. An JE*, Cho J*, Kim MJ, Lee AY, Sim WJ, Hong GU, Lee SH, Kim DS, Yi SY, Lee KM, Yu SY#. Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review. Reviews in Cardiovascular Medicine (Q3). 2026 May 27;27(5):46524.

8. An JE*, Kim NK*, Lee SH, Kim KH, Kim MJ, Lee AY, Hong GU, Sim WJ, Kim SI, Kong TW, Kwon BS, Min KJ#, Yu SY#. Factors affecting health-related quality of life in cervical cancer survivors: a multicenter cross-sectional study in Korea. BMC Women's Health (Q1). 2026 Apr 27.

9. Lim W*, Lee NR, Shin HG, Yu SY, Park SK#. IARC Group 1 Pharmaceuticals and Associated Cancer Risks: A Nationwide Population-Based Cohort Study in Korea. Cancer Research and Treatment (Q1). 2026 Apr 1;58(2):376-92.

10. Jang S*, Cheong C*, Choi WS, Kim KH, An JE, Cho J, Yu SY#. Transitioning to routine immunization: Cost-effectiveness of a national COVID-19 vaccination program for older adults in South Korea. International Journal of Infectious Diseases (Q1). 2026 Mar 23:108585.

11. 김윤희*, 박미혜, 박은자, 유수연, 홍지형, 배은영#. 선별등재제도 도입 20년에 대한 이해관계자 인식 조사. HIRA Research. Under review.

12. 이성제*, 유수연#. 고혈압 환자의 자가보고 복약이행과 상용치료의사 보유의 관련성. 약학회지. Under review.

13. 신주영*, 고연지, 김태은, 김예은, 김정선, 김우림, 유수연#. 지역사회 기반 약물관리사업 참여자의 복약이행 및 다제약물 사용 현황. 한국사회약학회지. Under review.

14. 이은비*, 류인호, 안지은, 유수연#. 국내 예방접종 백신의 미충족 수요 분석. 약학회지. Under review.

15. 이아연*, 김시아, 안지은, 홍경우, 심우정, 이수현, 유수연#. 인유두종바이러스 감염 질환 환자에서의 건강 관련 삶의 질: EQ-5D-5L과 HINT-8의 비교. J Health Technol Assess 2026;14(1):21-31

16. 유수연*, 박성민, 김동숙, 한은아#. 사용범위 확대 의약품의 약가 인하와 재정영향 분석. 약학회지. 2026 Jun;70(3):245-54.

17. 안지은*, 조자현, 정채림, 유수연#. 코로나 19 백신의 국내 효과에 대한 체계적 문헌고찰. 한국사회약학회지. 2026 May;14(1):44-51.

2025

1. Choi WS*, Kim KH*, Kim DS*, Lee SH, An JE, Yu SY#. Increased 30-day Mortality Risk in Coronavirus Disease 2019 Compared to Seasonal Influenza. International Journal of Infectious Diseases (Q1). 2025 Dec 17:108312.

2. Choi JB*, Kim DS, Shin CE, Yu SY, Lee KW, Lee SJ#. Expert Consensus Study on the Redesign of the Sexually Transmitted Infection Surveillance System in Korea. Journal of Korean Medical Science (Q2). 2025 Dec 2;41(1):e18.

3. Yun JE*, Lee KS*, Lee H, Lee SH, Jung JH, Hwang EC, Lee NR, Han WK, Yu SY#. Diagnostic accuracy of prostate-specific antigen and prostate-specific antigen density in patients suspected of having prostate cancer in South Korea: A large, multi-institutional registry. Investigative and clinical urology (Q2). 2025 Dec 17;67(1):32.

4. Kim JW*, Koo BS, Kim HS, Park JH, Park JJ, Park JO, Seok JG, Oh KH, Woo SH, Eun YG, Lee YS, Chung MK, Jeong WJ, Chung EJ, Ji YB, Yu SY, Lee SH, Lee SY, Cho KJ#. Quality of life in oropharyngeal cancer: a retrospective analysis of patient characteristics and treatment modalities. Annals of Surgical Oncology (Q1). 2025 Dec;32(13):9928-41.

5. Hong GU*, Koo BS, Kim MJ, Sim WJ, Lee AY, An JE, Yu SY, Lee SY#, Lee SH#. Validation of the health-related quality of life instrument with 8 items for assessing health-related quality of life in patients with oropharyngeal cancer: a comparison with the EQ-5D-5L. Health and quality of life outcomes (10%). 2025 Oct 16;23(1):104.

6. Cheong C*, Choi WS*, An JE, Cho J, Yoon YK, Yu SY#. Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea. Vaccine (Q2). 2025 Sep 17;63:127648.

7. Luu XQ*, Jun JK, Suh M, Oh JK, Yu SY, Choi KS#. Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination. JAMA Network Open (5%). 2025 Aug 12;8(8):e2526683.

8. Yu SY*, Kim DS, Kim H, Jo J, Kim H, Han E#. Assessment of financial impact of expanding the scope of drug usage in South Korea. International Journal of Health Policy and Management (10%). 2025 Jul 13;14:8812.

9. Kim MJ*, Koo BS, Cho KJ, Lee SH, Lee AY, Hong GU, Sim WJ, An JE, Lee SY#, Yu SY#. Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments. Oral oncology (10%). 2025 Jun 1;165:107342.

10. Jeon H*, Yu SY#, Chertkova O, Yun H, Ng YL, Lim YY, Efimenko I, Makhlouf DM. Real-world insights of patient voices with age-related macular degeneration in the Republic of Korea and Taiwan: an AI-based Digital Listening study by Semantic-Natural Language Processing. BMC Medical Informatics and Decision Making (Q2). 2025 Mar 18;25(1):137.

11. 김동숙*, 유수연#. 의약품 유통 구조의 문제점과 개선방안: 그룹 인터뷰 연구. KFDC 규제과학회지 (구 FDC 법제연구). 2025 Dec;20(2):131-9.

12. 신혜미*, 임은지, 박선아, 유수연#. 코로나 19 예방접종 정책과 정부의 비용 지원: 국제 비교 및 시사점. 약학회지. 2025 Jun;69(3):273-82.

2024

1. Choi WS*, Sung Y, Kim J, Seok H, Choe YJ, Cheong C, Cho J, Lee DW, Shin JY, Yu SY#. Prioritization of vaccines for introduction in the national immunization program in the Republic of Korea. Vaccines (Q2). 2024 Aug 4;12(8):886.

2. Choi SH*, Yu SY*, Kim J, Choi M, Choi YY, Choi JH, Yun KW, Choe YJ#. Efficacy and Safety of COVID-19 Vaccines in Adolescents: Systematic Review of Randomized Controlled Studies and Observational Studies. Pediatric Infection and Vaccine (Scopus). 2024;31(1):12-24.

3. Kim J*, Choe YJ*, Park J, Cho J, Cheong C, Oh JK, Park M, Shim E, Yu SY#. Comparative effects of bivalent, quadrivalent, and nonavalent human papillomavirus vaccines in the prevention of genotype-specific infection: a systematic review and network meta-analysis. Infection & Chemotherapy (Scopus). 2023 Nov 20;56(1):37.

4. Lim W*, Moon S, Lee NR, Shin HG, Yu SY, Lee JE, Kim I, Ko KP, Park SK#. Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis. Scientific reports (Q1). 2024 Jan 3;14(1):413.

5. Ryoo S*, Choi M, Yu SY, Yoon YK, Huh K, Joo EJ#. The effects of remdesivir on mortality and the requirement for mechanical ventilation in patients with COVID-19: a systematic review stratified by disease severity. The Korean journal of internal medicine (Q1). 2023 Dec 28;39(1):160.

6. 정채림*, 최원석, 윤영경, 성연희, 조자현, 유수연#. 대상포진 백신의 유효성에 대한 신속 체계적 문헌고찰. 보건의료기술평가. 2024 Jun;12(1):1-8.

7. 정채림*, 유수연*, 노가야, 김동숙, 한은아#. 외국의 약제 사용범위 확대 정책의 현황: 호주, 영국 및 일본. 약학회지. 2024 Oct;68(5):344-51.

2023

1. Yu SY*, Choi M, Ryoo S, Cheong C, Huh K, Yoon YK, Jeong SJ#. Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis. Plos one (Q1). 2023 Nov 28;18(11):e0294872.

2. Yu SY*, Choi M, Cheong C, Ryoo S, Huh K, Yoon YK, Choi J, Kim SB#. Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis. Journal of Microbiology, Immunology and Infection (Q2). 2023 Oct 1;56(5):909-20.

3. Park M*, Yu SY#, Jeon HL, Song I. Factors affecting health-related quality of life in patients with metastatic breast cancer. Journal of Breast Cancer (Q2). 2023 Jul 11;26(5):436.

4. Choi M*, Lee HJ, Yu SY, Kim J, Park J, Ryoo S, Kim I, Park DA, Yoon YK, Joh JS, Park S#. Two years of experience and methodology of Korean COVID-19 living clinical practice guideline development. Journal of Korean medical science (Q2). 2023 May 9;38(23).

5. Ryoo S*, Koh DH, Yu SY, Choi M, Huh K, Yeom JS, Heo JY#. Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. PLoS One (Q1). 2023 Mar 29;18(3):e0272826.

6. 김동숙*, 유수연#, 국내 의약품 도매업체 현황 및 유통금액 분석. 대한약국학회지. 2023 9(2):45-49.

2022

1. Yu SY*, Koh DH*, Choi M, Ryoo S, Huh K, Yeom JS, Yoon YK#. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerging microbes & infections (10%). 2022 Dec 31;11(1):1154-65.

2. Jin Y*, Jung JH*, Han WK, Hwang EC, Nho Y, Lee N, Yun JE, Lee KS, Lee SH, Lee H, Yu SY#. Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis. Investigative and clinical urology (Q2). 2022 Apr 21;63(3):251.

3. 최미영*, 유수연*, 정채림, 최영준, 최수한#. 5-11 세 소아에서 코로나 19 백신의 효능 및 안전성에 대한 체계적 문헌고찰. Pediatric Infection & Vaccine. 2022 Apr 1;29(1):28-36.

2021

1. Yu SY*#, Mckavanagh D, McPherson I, Walpole E, Atkinson V, Hollingworth S. Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real‐world study. Pharmacoepidemiology and Drug Safety. 2021 Oct;30(10):1371-9.

2. Hollingworth S*#, Fenny AP, Yu SY, Ruiz F, Chalkidou K. Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis. Cost Effectiveness and Resource Allocation. 2021 Jul 7;19(1):39.

3. Kim SB*, Kim J, Huh K, Choi WS, Kim YJ, Joo EJ, Kim YJ, Yoon YK, Heo JY, Seo YB, Yu SY, Jeong SJ#. Korean Society of Infectious Diseases/national evidence-based healthcare collaborating agency recommendations for anti-SARS-CoV-2 monoclonal antibody treatment of patients with COVID-19. Infection & Chemotherapy. 2021 Jun 18;53(2):395.

4. Kim SB*, Ryoo S, Huh K, Joo EJ, Kim YJ, Choi WS, Kim YJ, Yoon YK, Heo JY, Yu SY, Seo YB, Jeong SJ#. Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea collaborating agency guidelines on the treatment of patients with COVID-19. Infection & Chemotherapy. 2021 Mar 24;53(1):166.

5. Hollingworth S*, Mckavanagh D, McPherson I, Walpole E, Yu SY#. Research governance authorisation: the next frontier. Australian Health Review. 2021 Jan 28;45(3):389-92.

2020

1. Park JH*, Lee J, Yu SY, Jung JH, Han K, Kim DH, Rhee J#. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC geriatrics. 2020 Oct 15;20(1):407.

2. Yang J*, Choi M, Choi J, Kang M, Jo A, Chung SH, Sim SH, Kim YJ, Yang EJ, Yu SY#. Supervised physical rehabilitation in the treatment of patients with advanced cancer: a systematic review and meta-analysis. Journal of Korean medical science. 2020 Jul 27;35(29).

3. Yu SY*, Lee B#, McGuire TM, Lee HJ, Hollingworth SA. Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. European Journal of Clinical Pharmacology. 2020 Apr;76(4):547-55.

4. 이혜재*, 유수연#. 호주의 급여의약품 청구데이터의 활용에 대한 고찰: Atorvastatin 의 사용량과청구액 분석 사례를 중심으로. 한국임상약학회지. 2020 Jun;30(2):73-80.

2019 or before

1. Lee SO*, Yu SY#. Utilization patterns of coagulation factor consumption for patients with hemophilia. Journal of Korean Medical Science. 2016 Jan 1;31(1):33-8.

2. Yu SY*, Lee TJ#, Jang SH, Han JW, Kim TH, Kim KW. Cost-effectiveness of nationwide opportunistic screening program for dementia in South Korea. Journal of Alzheimer’s Disease. 2015 Jan 6;44(1):195-204.

3. Yu SY*#, Yang BM, Kim JH. New anti-rebate legislation in South Korea. Applied health economics and health policy. 2013 Aug;11(4):311-8.

4. 유수연*, 조현민, 강현아, 김수경#. 의료용 마약류 유통 관리에 대한 고찰과 정책적 함의: 유통자료 및 청구자료 분석을 중심으로. Korean Journal of Clinical Pharmacy. 2015 Jan;25(4):280-5.

5. 문유정*, 양봉민#, 유수연, 권준성. Personalized Medicine 의 보험급여 현황과 쟁점. 보건경제와 정책연구. 2013 Mar:23-39.